Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TICTAVI: Ticagrelor vs Lysine Acetylsalicylate-Clopidogrel in TAVI
NCT02817789Phase 3Terminated
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- May 2016
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of ticagrelor in aortic valve stenosis (2 arms), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoints: Valve Academic Research Consortium-2 composite endpoint at 30 days, Death at 30 days and 6 more. Started May 2016; status: terminated.
02
Drugs
ticagrelor
03
Conditions
aortic valve stenosis
Beyond the preview
Go deeper on NCT02817789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02817789.